Immunomodulation in Pancreatic Cancer

被引：14

作者：

Krishnamoorthy, Mithunah ^{[1
,2
]}

Lenehan, John G. ^{[3
]}

Burton, Jeremy P. ^{[1
,4
,5
]}

Vareki, Saman Maleki ^{[2
,6
,7
]}

机构：

[1] Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 3K7, Canada

[2] Lawson Hlth Res Inst, Canc Res Lab Program, London, ON N6A 5W9, Canada

[3] Univ Western Ontario, Dept Oncol, Div Med Oncol, London, ON N6A 3K7, Canada

[4] Lawson Hlth Res Inst, Canadian Ctr Human Microbiome & Probiot, London, ON N6A 4V2, Canada

[5] Univ Western Ontario, Dept Surg, Div Urol, London, ON N6A 3K7, Canada

[6] Univ Western Ontario, Dept Pathol & Lab Med, London, ON N6A 3K7, Canada

[7] Univ Western Ontario, Dept Oncol, Div Expt Oncol, London, ON N6A 3K7, Canada

来源：

CANCERS | 2020年 / 12卷 / 11期

关键词：

pancreatic cancer; pancreatic ductal carcinoma; immunotherapy; anti-PD1; microbiome; fecal microbiota transplant; T-cells; CD8(+) T-CELLS; SUPPRESSOR-CELLS; TUMOR MICROBIOME; NAB-PACLITAXEL; STELLATE CELLS; GEMCITABINE; IMMUNOTHERAPY; MACROPHAGES; DEPLETION; FIBROBLASTS;

D O I：

10.3390/cancers12113340

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Pancreatic cancer is an aggressive disease that has few options for treatment. Immune checkpoint blockers have been revolutionary in specific cancer types yet have not shown promise in pancreatic cancers. This review discusses components of the immune system needed for successful anti-tumor responses against pancreatic cancer and how these mechanisms can be exploited to develop new therapeutic strategies. Pancreatic cancer has a high mortality rate, and its incidence is increasing worldwide. The almost universal poor prognosis of pancreatic cancer is partly due to symptoms presenting only at late stages and limited effective treatments. Recently, immune checkpoint blockade inhibitors have drastically improved patient survival in metastatic and advanced settings in certain cancers. Unfortunately, these therapies are ineffective in pancreatic cancer. However, tumor biopsies from long-term survivors of pancreatic cancer are more likely to be infiltrated by cytotoxic T-cells and certain species of bacteria that activate T-cells. These observations suggest that T-cell activation is essential for anti-tumor immunity in pancreatic cancers. This review discusses the immunological mechanisms responsible for effective anti-tumor immunity and how immune-based strategies can be exploited to develop new pancreatic cancer treatments.

引用

页码：1 / 13

页数：13

共 70 条

[1] The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis [J].

Amin, Saber ;

Baine, Michael ;

Meza, Jane ;

Lin, Chi .

BMC CANCER, 2020, 20 (01)

[2] Pancreatic stellate cells: a starring role in normal and diseased pancreas [J].

Apte, Minoti V. ;

Pirola, Romano C. ;

Wilson, Jeremy S. .

FRONTIERS IN PHYSIOLOGY, 2012, 3

[3] Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer [J].

Balachandran, Vinod P. ;

Luksza, Marta ;

Zhao, Julia N. ;

Makarov, Vladimir ;

Moral, John Alec ;

Remark, Romain ;

Herbst, Brian ;

Askan, Gokce ;

Bhanot, Umesh ;

Senbabaoglu, Yasin ;

Wells, Daniel K. ;

Cary, Charles Ian Ormsby ;

Grbovic-Huezo, Olivera ;

Attiyeh, Marc ;

Medina, Benjamin ;

Zhang, Jennifer ;

Loo, Jennifer ;

Saglimbeni, Joseph ;

Abu-Akeel, Mohsen ;

Zappasodi, Roberta ;

Riaz, Nadeem ;

Smoragiewicz, Martin ;

Kelley, Z. Larkin ;

Basturk, Olca ;

Goenen, Mithat ;

Levine, Arnold J. ;

Allen, Peter J. ;

Fearon, Douglas T. ;

Merad, Miriam ;

Gnjatic, Sacha ;

Iacobuzio-Donahue, Christine A. ;

Wolchok, Jedd D. ;

DeMatteo, Ronald P. ;

Chan, Timothy A. ;

Greenbaum, Benjamin D. ;

Merghoub, Taha ;

Leach, Steven D. .

NATURE, 2017, 551 (7681) :512-+

[4] Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial [J].

Beatty, Gregory L. ;

O'Hara, Mark H. ;

Lacey, Simon F. ;

Torigian, Drew A. ;

Nazimuddin, Farzana ;

Chen, Fang ;

Kulikovskaya, Irina M. ;

Soulen, Michael C. ;

McGarvey, Maureen ;

Nelson, Anne Marie ;

Gladney, Whitney L. ;

Levine, Bruce L. ;

Melenhorst, J. Joseph ;

Plesa, Gabriela ;

June, Carl H. .

GASTROENTEROLOGY, 2018, 155 (01) :29-32

[5]

Beatty Gregory L, 2017, Am Soc Clin Oncol Educ Book, V37, P267, DOI 10.14694/EDBK_175232

[6] BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial [J].

Bockorny, Bruno ;

Semenisty, Valerya ;

Macarulla, Teresa ;

Borazanci, Erkut ;

Wolpin, Brian M. ;

Stemmer, Salomon M. ;

Golan, Talia ;

Geva, Ravit ;

Borad, Mitesh J. ;

Pedersen, Katrina S. ;

Park, Joon Oh ;

Ramirez, Robert A. ;

Abad, David G. ;

Feliu, Jaime ;

Munoz, Andres ;

Ponz-Sarvise, Mariano ;

Peled, Amnon ;

Lustig, Tzipora M. ;

Bohana-Kashtan, Osnat ;

Shaw, Stephen M. ;

Sorani, Ella ;

Chaney, Marya ;

Kadosh, Shaul ;

Haras, Abi Vainstein ;

Von Hoff, Daniel D. ;

Hidalgo, Manuel .

NATURE MEDICINE, 2020, 26 (06) :878-+

[7] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[8] CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype [J].

Candido, Juliana B. ;

Morton, Jennifer P. ;

Bailey, Peter ;

Campbell, Andrew D. ;

Karim, Saadia A. ;

Jamieson, Thomas ;

Lapienyte, Laura ;

Gopinathan, Aarthi ;

Clark, William ;

McGhee, Ewan J. ;

Wang, Jun ;

Escorcio-Correia, Monica ;

Zollinger, Raphael ;

Roshani, Rozita ;

Drew, Lisa ;

Rishi, Loveena ;

Arkell, Rebecca ;

Evans, T. R. Jeffry ;

Nixon, Colin ;

Jodrell, Duncan I. ;

Wilkinson, Robert W. ;

Biankin, Andrew V. ;

Barry, Simon T. ;

Balkwill, Frances R. ;

Sansom, Owen J. .

CELL REPORTS, 2018, 23 (05) :1448-1460

[9]

Chanyi RM, 2017, SAGE OPEN MED, V5, DOI 10.1177/2050312117708712

[10] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].

Conroy, T. ;

Hammel, P. ;

Hebbar, M. ;

Ben Abdelghani, M. ;

Wei, A. C. ;

Raoul, J. -L. ;

Chone, L. ;

Francois, E. ;

Artru, P. ;

Biagi, J. J. ;

Lecomte, T. ;

Assenat, E. ;

Faroux, R. ;

Ychou, M. ;

Volet, J. ;

Sauvanet, A. ;

Breysacher, G. ;

Di Fiore, F. ;

Cripps, C. ;

Kavan, P. ;

Texereau, P. ;

Bouhier-Leporrier, K. ;

Khemissa-Akouz, F. ;

Legoux, J. -L. ;

Juzyna, B. ;

Gourgou, S. ;

O'Callaghan, C. J. ;

Jouffroy-Zeller, C. ;

Rat, P. ;

Malka, D. ;

Castan, F. ;

Bachet, J. -B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406

← 1 2 3 4 5 6 7 →